Eric P Winer Selected Research

Neutropenia

10/2022	Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
1/2021	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
1/2021	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
1/2021	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer.
1/2020	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
12/2016	Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.
11/2016	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
1/2015	Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
9/2007	Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric P Winer Research Topics

Disease

260	Breast Neoplasms (Breast Cancer) 10/2022 - 06/2002
162	Neoplasms (Cancer) 10/2022 - 05/2002
34	Triple Negative Breast Neoplasms 01/2022 - 12/2008
21	Brain Neoplasms (Brain Tumor) 11/2020 - 01/2006
15	Neoplasm Metastasis (Metastasis) 01/2020 - 09/2004
14	Leukemia 01/2021 - 04/2003
13	Pathologic Complete Response 05/2022 - 02/2007
9	Neutropenia 10/2022 - 09/2007
8	Fatigue 10/2022 - 10/2013
7	Disease Progression 07/2022 - 06/2003
7	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 09/2012
5	Cardiotoxicity 02/2022 - 12/2004
4	Infections 01/2021 - 01/2015
4	Hypertension (High Blood Pressure) 01/2020 - 10/2014
4	Diarrhea 01/2020 - 12/2014
4	Neurologic Manifestations (Neurological Manifestations) 01/2019 - 09/2004
4	Heart Failure 10/2018 - 09/2010
4	Central Nervous System Diseases (CNS Diseases) 03/2016 - 03/2007
3	Amenorrhea 08/2021 - 01/2005
3	Circulating Neoplastic Cells 01/2021 - 11/2014
3	Nausea 01/2020 - 12/2004
3	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 11/2015 - 11/2006
3	Osteoporosis 01/2012 - 01/2005

Drug/Important Bio-Agent (IBA)

62	Hormones (Hormone)IBA 10/2022 - 08/2002
50	Trastuzumab (Herceptin)FDA Link 10/2022 - 06/2002
43	Paclitaxel (Taxol)FDA LinkGeneric 05/2022 - 06/2002
34	human ERBB2 proteinIBA 10/2022 - 01/2003
31	ErbB Receptors (EGF Receptor)IBA 10/2022 - 10/2007
31	Estrogen ReceptorsIBA 01/2022 - 01/2003
25	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2003
25	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2003
25	Tamoxifen FDA LinkGeneric 01/2019 - 08/2002
23	Aromatase InhibitorsIBA 01/2019 - 08/2002
21	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2006
12	AnthracyclinesIBA 10/2022 - 01/2003
12	Capecitabine (Xeloda)FDA Link 10/2020 - 12/2004
12	Lapatinib (GW572016)FDA Link 11/2018 - 12/2007
11	Biological ProductsIBA 12/2020 - 06/2006
10	taxaneIBA 10/2022 - 09/2007
10	Letrozole (Femara)FDA LinkGeneric 10/2022 - 01/2003
10	Ado-Trastuzumab EmtansineIBA 10/2022 - 09/2012
10	Bevacizumab (Avastin)FDA Link 01/2022 - 12/2008
9	Phenobarbital (Luminal)FDA Link 01/2021 - 10/2011
9	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 06/2006
8	pertuzumabIBA 10/2022 - 10/2013
7	130-nm albumin-bound paclitaxelIBA 11/2021 - 07/2015
7	Fluorouracil (Carac)FDA LinkGeneric 10/2019 - 04/2006
6	Fulvestrant (Faslodex)FDA Link 01/2022 - 12/2014
6	Cell-Free Nucleic AcidsIBA 01/2022 - 11/2017
6	PlatinumIBA 10/2021 - 10/2014
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2016
6	Estrogens (Estrogen)FDA Link 01/2021 - 01/2008
6	Pharmaceutical PreparationsIBA 01/2020 - 02/2003
6	exemestane (Aromasin)FDA Link 07/2018 - 09/2007
5	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 07/2012
5	pembrolizumabIBA 01/2022 - 01/2020
5	atezolizumabIBA 01/2022 - 11/2018
5	cabozantinibIBA 08/2021 - 11/2016
5	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 03/2010
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2002
5	Anastrozole (Arimidex)FDA LinkGeneric 02/2009 - 08/2002
5	Vinorelbine (Navelbine)FDA LinkGeneric 12/2008 - 08/2003
4	palbociclibIBA 10/2022 - 11/2020
4	B7-H1 AntigenIBA 01/2022 - 11/2018
4	neratinibIBA 01/2022 - 03/2016
4	AlpelisibIBA 01/2022 - 01/2019
4	Messenger RNA (mRNA)IBA 01/2022 - 03/2015
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
4	Methotrexate (Mexate)FDA LinkGeneric 10/2019 - 05/2009
3	ribociclibIBA 10/2022 - 11/2016
3	Taxoids (Taxanes)IBA 10/2022 - 12/2004
3	olaparibIBA 01/2022 - 10/2014
3	Circulating Tumor DNAIBA 01/2022 - 01/2021
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 10/2010
3	Cyclin-Dependent Kinase 4IBA 01/2022 - 12/2019
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 11/2005
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2021 - 10/2010
3	LigandsIBA 10/2020 - 06/2003
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 12/2008
3	ixabepilone (BMS 247550)FDA Link 01/2020 - 07/2015
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020 - 02/2007
3	Epidermal Growth Factor (EGF)IBA 01/2019 - 12/2012
3	SteroidsIBA 01/2019 - 02/2006
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2018 - 11/2016
3	Tumor Biomarkers (Tumor Markers)IBA 01/2017 - 06/2003
3	Tyrosine Kinase InhibitorsIBA 11/2016 - 01/2004
3	Phosphotransferases (Kinase)IBA 11/2016 - 01/2004
3	Gemcitabine FDA Link 01/2016 - 12/2004
3	iniparibIBA 01/2016 - 08/2014

Therapy/Procedure

158	Therapeutics 10/2022 - 08/2002
72	Drug Therapy (Chemotherapy) 01/2022 - 06/2002
27	Adjuvant Chemotherapy 05/2022 - 04/2003
17	Radiotherapy 01/2022 - 09/2004
13	Mastectomy (Mammectomy) 01/2022 - 02/2009
12	Neoadjuvant Therapy 02/2022 - 09/2013
12	Segmental Mastectomy (Lumpectomy) 01/2022 - 11/2008
10	Aftercare (After-Treatment) 04/2021 - 12/2003
4	Immunotherapy 01/2020 - 01/2017
3	Prophylactic Mastectomy 11/2015 - 09/2013
3	Combination Drug Therapy (Combination Chemotherapy) 03/2015 - 04/2003